Athens, 23.02.2022 TIKUN Europe, the first pharmaceutical company active in the field of medical cannabis, in Greece, announces the founding of its subsidiary company, TIKUN Europe Netherlands BV, which will be based in Amsterdam.
The newly founded company will be responsible for the marketing,2 sale and distribution of TIKUN Europe’s CBD line in the European market.
The product line which will be launched initially in the Greek market this coming Spring, introduces new, innovative CBD products developed by the «Research and Development (R&D) Department» of TIKUN Europe. This R&D unit is based in Greece and has created original CBD product formulas, manufactured in a certified factory in France, under the most rigorous quality standards.
TIKUN Europe’s activity is fully aligned with the Greek legislation provisions for the cultivation and processing of medical cannabis, aiming at the creation of pharmaceutical formulations that are produced in a GMP environment, whilst applying strict control standards and procedures to ensure high quality and safety. TIKUN Europe Netherlands BV, which is not a pharmaceutical company, will be responsible for the CBD product line.
TIKUN is a pioneering company in the research, development, and production of medicinal cannabis products worldwide. Defining the market of medicinal cannabis in 2005, it began its activity in Israel and in the course of time expanded with production units in the USA, Canada, Australia, Asia (Israel) and Europe (based in Greece). With more than 15 years of clinical and laboratory studies and an extensive database of tens of thousands of patients worldwide, TIKUN’s innovative pharmaceutical formulations are based on cannabis strains that have been awarded worldwide. Its medications offer support for serious conditions, such as Parkinson’s disease, Crohn’s disease, Autism, multiple sclerosis, epilepsy, side effects from chemotherapy, neuropathic pain, etc.
About TIKUN Europe
TIKUN Olam Europe’s presence in Europe began in Greece, taking advantage of the country’s potential to develop into an international center for the production of medicinal cannabis, with most of the production aimed for exportation to European countries.
With a total investment of €40m, in a 56,000m2 area in Corinth, TIKUN Europe has created the largest, for this sector, production unit in Europe, with a vertically integrated production process and an R&D department, in state-of-the-art facilities and with equipment of latest technology.
TIKUN Europe’s activity is fully aligned with the Greek legislation provisions for the cultivation and processing of medical cannabis, aiming at the creation of pharmaceutical formulations that will be produced in a GMP environment and by applying strict control standards and procedures which ensure high quality and safety.
The company utilizes TIKUN’s know-how, while having direct access to its large patient database. TIKUN’s pharmaceutical formulations have effectiveness which has been verified following clinical studies and Real-World Data (RWD).
At the beginning of 2022, TIKUN Europe will launch its CBD product line, which is produced in a certified factory in France, based on innovative formulas developed by its R&D division. The TIKUN CBD series helps with the everyday life annoyances, while at the same time benefits the entire human body. In other words, it ensures homeostasis, providing holistic, natural balance.
V+O Communication, Vaia Skandali (+30) 210.72.49.000 / (+30) 6936.567.731, Email firstname.lastname@example.org email@example.com